Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dapagliflozin/Metformin XR FDC vs Co-administration
NCT04856007Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from zero to the last quantifiable concentration, Area under the plasma concentration-time curve from zero to infinity and 1 more. Started Apr 2021; status: completed.
02
Drugs
dapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04856007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856007.